Ameritas Investment Partners, Inc. Viking Therapeutics, Inc. Transaction History

Ameritas Investment Partners, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.4 - $94.5 $12,614 - $68,512	725 Added 7.59%	10,278 $842,000
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $17,613 - $25,808	1,613 Added 20.31%	9,553 $105,000
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $117,829 - $196,832	7,940 New	7,940 $128,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $11,716 - $17,491	-5,553 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $9,832 - $13,627	1,282 Added 30.02%	5,553 $46,000
Q3 2018 Nov 13, 2018	SELL	$9.7 - $19.65 $902 - $1,827	-93 Reduced 2.13%	4,271 $74,000
Q2 2018 Aug 13, 2018	BUY	$3.88 - $12.74 $16,932 - $55,597	4,364 New	4,364 $41,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.